Signal Genetics Buying ChipDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing firm Signal Genetics has agreed to buy molecular diagnostics company ChipDx for an undisclosed amount.

Under the terms of the deal announced today, Signal will acquire all of ChipDx's assets, including its patents for its prognostic tests for lung, breast, and colon cancers. It is buying BreastGeneDX, ColonGeneDX, and LungGeneDX, as well as all diagnostic and prognostic tests under development by ChipDx.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.